Philadelphia, PANCT03301038Now EnrollingIRB Ready

Idiopathic Infantile Hypercalcaemia - Severe Form Clinical Trial in Philadelphia, PA

Access cutting-edge idiopathic infantile hypercalcaemia - severe form treatment through this phase 2 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Children's Hospital of Philadelphia

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access idiopathic infantile hypercalcaemia - severe form specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related idiopathic infantile hypercalcaemia - severe form treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this idiopathic infantile hypercalcaemia - severe form clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Idiopathic Infantile Hypercalcaemia - Severe Form Study in Philadelphia

This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.

Sponsor: Children's Hospital of Philadelphia

Who Can Participate

Inclusion Criteria

Males or females age 6 months to 65 years.
at least one mutations of CYP24A1
Serum and/or urinary calcium above the normal reference range for age
Serum PTH concentration \<20 pg/ml
Elevated or normal serum concentration of 1,25-dihydroxyvitamin D3.

Exclusion Criteria

Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
Allergy to rifampin or related medications
Current therapies with medications that have significant drug-drug interactions with rifampin, defined as a medication considered to interact with CYP3A4 or CYP3A5 and either induce or inhibit expression or function of these P450 enzymes. By "drug-drug" interactions we are looking for medications that will affect metabolism or action of rifampin as exclusionary, not medications that will be affected by rifampin.
Pregnancy or breastfeeding
Laboratory abnormalities that indicate clinically significant hepatic, or renal disease:
Aspartate Aminotransferase (AST/SGOT) \> 2.0 times the upper limit of normal Alanine aminotransferase (ALT/SGPT) \> 2.0 times the upper limit of normal Total bilirubin \> 2.0 times the upper limit of normal Creatinine \> 2.0 times the upper limit of normal

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT03301038) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Idiopathic Infantile Hypercalcaemia - Severe Form Treatment Options in Philadelphia, PA

If you're searching for idiopathic infantile hypercalcaemia - severe form treatment options in Philadelphia, PA, this clinical trial (NCT03301038) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced idiopathic infantile hypercalcaemia - severe form specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all idiopathic infantile hypercalcaemia - severe form clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Philadelphia, PA

See all heart attack clinical trials recruiting in Philadelphia — not just this study.

Browse Heart Attack Trials in Philadelphia →

Browse More Trials by Condition

Heart Attack TrialsPulmonary Embolism TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA